Your central resource for PET educational materials, including evidence-based publications, clinical case studies, and product resources. Check out the new SOFIE Education Hub Go to …

With our premier radiopharmacy network, mature contract manufacturing services and high value theranostic intellectual property, SOFIE is dedicated to improving patient health.

SOFIE has built a high-capacity PET radiopharmaceutical network capable of delivering large volumes of products to as many patients as possible. Our product lines include FDG, Pylarify, …

Our team works alongside our Pharma and Academic partners to revolutionize clinical diagnostics and therapeutics to better understand and treat the biology of disease.

In Nov 2019, SOFIE Biosciences (SOFIE) licensed quinoline-based PET tracers, developed by the team at Heidelberg University, that act as FAP inhibitors (FAPI) and showed promising …

GE HealthCare and SOFIE Biosciences (SOFIE) announced a partnership to develop, manufacture and commercialize SOFIE’s Gallium-68 and Fluorine-18 labelled diagnostics …

Transparency in Coverage (TiC) regulations requires health insurers and group Health Plans to post their provider link on company websites. View SOFIE’s Link here View our Privacy Policy

Nov 17, 2025 · SOFIE is launching a second Phase 3 study, FAPI-PRO (FAPI in Precision Imaging of Pancreatic Cancer), starting December 2025, focused on Pancreatic Ductal …

SOFIE is dedicated to providing reliable, high quality radiopharmaceuticals and cutting-edge technologies

Oct 1, 2025 · With its robust radiopharmaceutical production and distribution network, mature contract manufacturing services, and now, high-value theranostic intellectual property, SOFIE …